This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01685060
First received: September 4, 2012
Last updated: May 25, 2017
Last verified: May 2017
September 4, 2012
May 25, 2017
November 26, 2012
March 29, 2016   (Final data collection date for primary outcome measure)
Overall Response Rate (ORR) to LDK378 Per Investigator Assessment [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
ORR per RECIST 1.1 calculated as the percentage of patients with a best overall confirmed response defined as complete response or partial response (CR+PR) as assessed by investigator. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Overall response rate (ORR) to LDK378 by investigator assessment [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
ORR per RECIST v1.1 calculated as the proportion of patients with a best overall response defined as complete response or partial response (CR+PR) as assessed by investigator
Complete list of historical versions of study NCT01685060 on ClinicalTrials.gov Archive Site
  • ORR Per Blinded Independent Review Committee (BIRC) Assessment [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    ORR (CR+PR) by BIRC is calculated as the percentage of patients with a best overall confirmed response defined as complete response or partial response (CR+PR) as assessed by BIRC. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
  • Duration of Response (DOR) by Investigator [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    DOR, calculated as the time from the date of the first confirmed CR or PR to the first documented progression or death due to any cause, by investigator. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
  • Duration of Response (DOR) by BIRC [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    DOR, calculated as the time from the date of the first documented CR or PR to the first documented progression or death due to underlying cancer, by BIRC (Blinded Imaging Review Committee). CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
  • Disease Control Rate (DCR) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    DCR was calculated as the percentage of patients with best overall response of CR, PR, SD, or non-CR non-PD (NCRNPD), per RECIST 1.1 by investigator. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. Non-CR/Non-PD (NCRNPD): refers to best overall responses that are neither CR nor PD per RECIST 1.1 criteria for patients with non-measurable disease only at baseline.
  • Time to Response (TTR) Per Investigator [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    TTR is the time from date of start of treatment to the first CR or PR observed which were confirmed afterwards.
  • Time to Response (TTR) Per BIRC [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    TTR is the time from date of start of treatment to the first CR or PR observed which are confirmed afterwards.
  • Progression-free Survival (PFS) Per Investigator [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    PFS, defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient had no event or when the patient received any further anticancer therapy in the absence of disease progression, progression-free survival was censored at the date of last adequate tumor assessment.
  • Progression-free Survival (PFS) Per BIRC [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    PFS, defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient had no event or when the patient received any further anticancer therapy in the absence of disease progression, progression-free survival was censored at the date of last adequate tumor assessment.
  • Overall Intracranial Response Rate (OIRR) Per Investigator [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    OIRR calculated as the ORR (CR+PR) of lesions in the brain for patients who had measureable disease in the brain at baseline.
  • Overall Intracranial Response Rate (OIRR) Per BIRC [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    OIRR calculated as the ORR (CR+PR) of lesions in the brain for patients who had measureable disease in the brain at baseline.
  • Overall Survival (OS) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    OS, defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive.
  • Duration of response (DOR) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    DOR, calculated as the time from the date of the first documented CR or PR to the first documented progression or death due to underlying cancer, by investigator and BIRC (Blinded Imaging Review Committee)
  • Disease control rate (DCR) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    DCR, calculated as the proportion of patients with best overall response of CR, PR, or SD, by investigator and BIRC
  • Time to Response (TTR) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    TTR, calculated as the time from first dose of LDK378 to first documented response (CR+PR), by investigator and BIRC
  • ORR by BIRC assessment [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    ORR (CR+PR) per RECIST v1.1 as assessed by BIRC
  • Safety profile [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    Adverse events and laboratory abnormalities
  • Progression-free survival (PFS) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    PFS, defined as time from first dose of LDK378 to progression or death due to any cause, as assessed by BIRC and investigator assessment
  • Overall Survival (OS) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]
    OS, defined as time from first dose of LDK378 to death due to any cause
Not Provided
Not Provided
 
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib
A single-arm, open-label, multicenter, phase II study. Treatment with LDK378 750 mg qd continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of the investigator or patient, started a new anti-cancer therapy and/or died. LDK378 could be continued beyond RECIST-defined progressive disease (PD) as assessed by the investigator if, in the judgment of the investigator, there was evidence of clinical benefit. In these patients tumor assessment would continue as per the schedule of assessments until treatment with LDK378 was permanently discontinued. Patients who discontinued the study medication in the absence of progression continued to be followed for tumor assessment until the time of PD as assessed by the investigator
Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Non-Small Cell Lung Cancer
Drug: LDK378
Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
Other Name: Ceritinib
Experimental: LDK378
Patients treated with ceritinib/LDK378 750 mg once-daily, fasted
Intervention: Drug: LDK378
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
140
March 29, 2016
March 29, 2016   (Final data collection date for primary outcome measure)

Inclusion critieria:

  • Histologically or cytologically confirmed diagnosis of stage IIIB or IV NSCLC that carries an ALK rearrangement, as per the FDA-approved FISH assay (Abbott Molecular Inc.).
  • Age 18 years or older at the time of informed consent.
  • Patients must have NSCLC that has progressed during therapy with crizotinib or within 30 days of the last dose
  • Patients must have received 1-3 lines of cytotoxic chemotherapy (of which 1 must have been a platinum doublet) to treat their locally advanced or metastatic NSCLC
  • Patients must have a tumor tissue sample available, collected either at the time of diagnosis of NSCLC or any time since.
  • Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study.

Exclusion criteria:

  • Patients with known hypersensitivity to any of the excipients of LDK378.
  • Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.
  • History of carcinomatous meningitis.
  • Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.
  • Clinically significant, uncontrolled heart disease
  • Systemic anti-cancer therapy given after the last dose of crizotinib and prior to starting study drug.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   France,   Germany,   Hong Kong,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Singapore,   Spain,   United Kingdom,   United States
Australia,   Belgium,   Sweden
 
NCT01685060
CLDK378A2201
2012-003432-24 ( EudraCT Number )
Yes
Not Provided
Not Provided
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP